<DOC>
	<DOCNO>NCT00745108</DOCNO>
	<brief_summary>Tibolone register treatment climacteric symptom prevention postmenopausal osteoporosis . This 2-year study confirm endometrial safety tibolone comparison CE/MPA .</brief_summary>
	<brief_title>Tibolone Endometrium Study ( Study 32972 ) ( P06470 )</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Tibolone</mesh_term>
	<criteria>Healthy postmenopausal woman , 45 65 year age intact uterus . Women must postmenopausal less 15 year , atrophic inactive endometrium , body mass index 18 32 kg/ m2 ( inclusive ) . Final diagnosis endometrial biopsy 'no tissue ' 'tissue insufficient diagnosis ' . Double layer endometrial thickness &gt; 6 mm assess transvaginal ultrasonography ( TVUS ) . Any previous current unopposed estrogen administration tamoxifen citrate . Any unexplained vaginal bleeding follow menopause . Women abnormal Pap smear test result ( PAP IIb high ) Previous use raloxifene hydrochloride longer one month .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>